Bloomberg Stock Movers
2026-09-08 · Hosted by — · Bloomberg / iHeartMedia
Executive Summary
Tuesday's Stock Movers roundup was dominated by bad news in healthcare and a bright spot in semiconductors. Novartis shares plunged the most since 2020 after its muscle-wasting disease treatment failed to meet its primary endpoint — the third clinical trial setback in a single week, following a failed heart medication study and another halted trial. The news dragged down biotech peers including Amgen, which is running its own late-stage heart disease drug trial.
Key Stories & Changes
1. Novartis Plunges on Third Failed Trial in a Week
Novartis shares fell the most since 2020 after its muscle-wasting disease treatment failed to meet its primary endpoint in a clinical trial
At least one analyst called it another "major pipeline setback"
Follows two other recent setbacks:
A new heart medication failed in a final-stage study (reported the prior day)
A trial for another drug was halted last week
Described by hosts as a "one, two, three punch" — three clinical trial setbacks in a single week
Biotech sector broadly weakened on the news, with Amgen shares dragged down as it is also in late-stage testing of its own heart disease drug
2. Boston Scientific Cyberattack Hits Financial Guidance
Boston Scientific disclosed it is unlikely to meet previously provided net sales growth and adjusted earnings guidance ranges for both Q3 and the full year
The cybersecurity incident was first identified on August 25
Impacted systems used to process and ship customer orders, and also affected manufacturing
Company anticipates recovering some portion of impacted revenue as operations ramp back up
Some employees reported canceled shifts and lack of information about day-to-day working plans
Hosts noted the incident is part of a broader string of recent cyberattacks hitting the MedTech sector, including some top industry companies
3. Intel Rises on Reported Price Hike Plans
Intel shares were among the most active pre-market names, outperforming
Reports indicate Intel is planning to lift prices on its central processing units (CPUs) by 10%, effective early October
Sourced to Taiwan technology publication Digitimes, citing unnamed sources
Would follow a price-raising pattern the report says started at the end of 2025
Attributed to supply chain costs and strong demand, per the report
Intel did not immediately respond to a request for comment
Trends Identified
1. Pipeline Risk Concentration in Pharma
Novartis's back-to-back-to-back trial failures illustrate how quickly confidence in a drugmaker's growth profile can erode when multiple late-stage assets fail in close succession. The spillover into Amgen shows investors are re-pricing risk across the broader cardiovascular and muscle-disease drug development space, not just the company directly affected.
2. Cybersecurity as a Financial Materiality Event
Boston Scientific's guidance miss shows cyberattacks have moved beyond a reputational or IT problem into a direct driver of reported financial results — order processing, shipping, and manufacturing disruptions translate straight into missed sales and earnings targets. Hosts flagged this as part of a pattern of attacks across the MedTech sector, suggesting healthcare device makers are an active target class.
3. Semiconductor Pricing Power
Reports of a 10% Intel CPU price increase, if confirmed, would extend a pricing pattern the report traces back to late 2025, pointing to sustained supply chain cost pressure and resilient chip demand supporting hardware margins. ---
Sentiment Analysis
Overall Market Sentiment: Mixed
Hosts framed the episode explicitly as a "good news, bad news morning," with healthcare names under pressure offset by strength in semiconductors.
Risk Factors Highlighted
Novartis pipeline attrition: Three separate clinical trial setbacks in one week raise doubts about the company's near-term growth profile.
Cross-company biotech contagion: Amgen and other biotech names fell in sympathy with Novartis despite no company-specific news of their own.
Boston Scientific guidance miss: The company itself says it is unlikely to hit previously provided Q3 and full-year sales and earnings targets.
Cyberattack operational disruption: The incident affected order processing, shipping, and manufacturing, with employees reporting canceled shifts.
Sector-wide MedTech cyber exposure: Hosts noted this is one of several recent attacks on top MedTech companies, suggesting an ongoing threat pattern.
Unconfirmed sourcing on Intel price hikes: The reported 10% CPU price increase is based on a single Taiwanese publication citing unnamed sources, and Intel has not confirmed it.
This episode was covered in today's [The Market Signal — 2026-09-08](https://marketsignal.beehiiv.com/p/the-market-signal-2026-09-08), a cross-source synthesis of multiple podcast reports.